There is an ongoing phase II randomized controlled study (21), which aims to explore whether the nintedanib combined albumin paclitaxel and platinum-containing regimens prolong the interval to AE-IPF, and the results of this study are expected in the future. Here, ALB is linked to idiopathic pulmonary fibrosis.